95 related articles for article (PubMed ID: 19015590)
1. The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.
Sasamura H; Nakaya H; Julius S; Takebayashi T; Sato Y; Uno H; Takeuchi M; Ishiguro K; Murakami M; Ryuzaki M; Itoh H;
Hypertens Res; 2008 Oct; 31(10):1843-9. PubMed ID: 19015590
[TBL] [Abstract][Full Text] [Related]
2. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of regression of hypertension using contemporary antihypertensive agents.
Sasamura H; Nakaya H; Julius S; Tomotsugu N; Sato Y; Takahashi F; Takeuchi M; Murakami M; Ryuzaki M; Itoh H;
Am J Hypertens; 2013 Dec; 26(12):1381-8. PubMed ID: 24190927
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
8. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
10. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
[TBL] [Abstract][Full Text] [Related]
11. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
12. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
[TBL] [Abstract][Full Text] [Related]
13. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
18. [Clinical implications from the results of the CASE-J extension].
Yasuno S; Fujimoto A; Ueshima K
Nihon Rinsho; 2012 Mar; 70(3):519-27. PubMed ID: 22514936
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
20. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Asmar R; Porcellati C; Dusing R
Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]